Current Status of the Management of Mendelian Susceptibility to Mycobacterial Disease in Mainland China
Journal of Clinical Immunology · Published 2019-08-01 · Available online 31 Jul 2019 · Journal article · DOI 10.1007/s10875-019-00672-x · Cited by 26 (Crossref)
Authors (11)
Wenjing Ying, Danru Liu, Xiaolong Dong, Wenjie Wang, Xiaoying Hui, Jia Hou, Haili Yao, Qinhua Zhou, Bijun Sun, Jinqiao Sun, Xiaochuan Wang
Abstract
PubPorta does not have an abstract for this article yet.
Read the article at the publisher →
Publication details
- Volume
- 39
- Issue
- 6
- Pages
- 600-610
- Year
- 2019
Citation
Ying, W., Liu, D., Dong, X., et al. (2019). Current Status of the Management of Mendelian Susceptibility to Mycobacterial Disease in Mainland China. Journal of Clinical Immunology. https://doi.org/10.1007/s10875-019-00672-x
Related articles
- Evolution of Inborn Errors of Immunity in China: Discoveries and Treatment Paradigms · Clinical Reviews in Allergy and Immunology · 2026 · Cites or is cited by this article
- Genetic Diagnosis and Identification of a Novel De Novo RELA Variant in Familial Behçet-like Autoinflammatory Syndrome Type 3: A Case Report · Journal of Clinical Immunology · 2026 · Same journal
- Biallelic MCM10 Deficiency Presenting with Natural Killer Cell Deficiency, Poikiloderma and EBV-Associated Malignancy · Journal of Clinical Immunology · 2026 · Same journal
- Hypoproteinemia and Hypogammaglobulinemia Due to a Homozygous FCGRT Mutation · Journal of Clinical Immunology · 2026 · Same journal
- Disseminated Tuberculosis and Early-Onset SLE in a Child with a Novel STAT1 Gain-of-Function Mutation: a Case Report · Journal of Clinical Immunology · 2026 · Same journal
- Humoral Immune Abnormalities in Transient Childhood Neutropenia: Insights From a 10-year Cohort Study in a Tertiary Center · Journal of Clinical Immunology · 2026 · Same journal
- Phenotypic Heterogeneity in CD40 Ligand Deficiency: Long-term Follow-up of a Patient with the c.156G > A Splice Variant · Journal of Clinical Immunology · 2026 · Same journal
- First-in-Human, Phase 1, Randomized, Double-Blind, Placebo-Controlled Study of TNX-1500, an Fc-Modified anti-CD154 Monoclonal Antibody, Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Ascending Doses in Healthy Adults · Journal of Clinical Immunology · 2026 · Same journal
- Antigen Microarray Reveals Broad and Subclinical Autoimmunity in Patients with Inborn Errors of Immunity · Journal of Clinical Immunology · 2026 · Same journal
- Continuous Infusion of the CXCR4 Antagonist Plerixafor for WHIM Syndrome · Journal of Clinical Immunology · 2026 · Same journal
Metrics
- Citations (Crossref)
- 26